Filtered By:
Condition: Cholesterol
Procedure: Dialysis

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 102 results found since Jan 2013.

Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome Results From the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome)
ConclusionsHigh-dose rosuvastatin given on admission to statin-naïve patients with ACS who are scheduled for an early invasive procedure can prevent CI-AKI and improve short-term clinical outcome. (Statin Contrast Induced Nephropathy Prevention [PRATO-ACS]; NCT01185938)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - January 7, 2014 Category: Radiology Source Type: research

Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome: Results From the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome)
Conclusions: High-dose rosuvastatin given on admission to statin-naïve patients with ACS who are scheduled for an early invasive procedure can prevent CI-AKI and improve short-term clinical outcome. (Statin Contrast Induced Nephropathy Prevention [PRATO-ACS]; NCT01185938)
Source: Journal of the American College of Cardiology - September 27, 2013 Category: Cardiology Authors: Mario Leoncini, Anna Toso, Mauro Maioli, Francesco Tropeano, Simona Villani, Francesco Bellandi Tags: Cardiac Imaging Source Type: research

Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis
Commentary on: Palmer SC, Craig JC, Navaneethan SD, et al.. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263–75. Context High-quality evidence suggests that chronic kidney disease (CKD) should now be considered a coronary heart disease (CHD) risk equivalent. Although statin therapy consistently reduces coronary events in the general population, the clinical benefits of lipid lowering in persons with CKD are less certain. Although multiple studies have shown possible benefit from statin therapy in early-stage CKD patients, ...
Source: Evidence-Based Medicine - September 19, 2013 Category: Internal Medicine Authors: Krishnan, S., Jacobson, T. A. Tags: Epidemiologic studies, Immunology (including allergy), Drugs: cardiovascular system, Stroke, Interventional cardiology, Ischaemic heart disease, Renal medicine Therapeutics Source Type: research

HMG CoA reductase inhibitors (statins) for dialysis patients.
CONCLUSIONS: Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels. PMID: 24022428 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 11, 2013 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research

The association of Klotho gene polymorphism with the mortality of patients on maintenance dialysis.
Abstract Despite medical progress, high morbidity and mortality rates have persisted in patients with end-stage renal disease (ESRD). The role in atherosclerosis and cardiovascular disease of klotho, an aging process-related gene, has been highlighted. Genetic variation in klotho has been reported to be a risk factor for coronary artery disease and ischemic stroke. Regarding the significance of cardiovascular disease for the outcome of ESRD patients, we investigated whether genetic variation of klotho was associated with mortality in ESRD patients on hemodialysis. 478 patients on maintenance hemodialysis for more ...
Source: Clinical Nephrology - September 2, 2013 Category: Urology & Nephrology Authors: Ko GJ, Lee YM, Lee EA, Lee JE, Bae SY, Park SW, Park MS, Pyo HJ, Kwon YJ Tags: Clin Nephrol Source Type: research

The beneficial effects of statins in patients undergoing hemodialysis
Abstract: Background: The beneficial effects of statins in patients undergoing hemodialysis are controversial. Our study aimed to investigate the use of statins and the subsequent risk of cardiovascular morbidity and mortality in patients undergoing hemodialysis.Methods: We conducted a cohort study using data from the Taiwan National Health Insurance Research Database. Cox regressions were performed to determine the hazard ratio (HR) of cardiovascular morbidity and mortality in the HD patients taking statins (statin cohort) compared with a propensity-matched comparison cohort.Results: The statin cohort included a total of ...
Source: International Journal of Cardiology - August 7, 2013 Category: Cardiology Authors: Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji Chen, Chia-Min Chung, Po-Hsun Huang, Shing-Jong Lin, Jaw-Wen Chen, Hsin-Bang Leu Tags: Original Articles Source Type: research

Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001--2010
Conclusions: Individuals with CKD have a high prevalence of CV-related comorbidities. However, attainment of LDL-C or BP goals was low regardless of disease stage. These findings highlight the potential for intensive risk factor modification to maximize CV event reduction in CKD patients at high risk for CHD.
Source: BMC Nephrology - June 27, 2013 Category: Urology & Nephrology Authors: Andreas KuznikJack MardekianLisa Tarasenko Source Type: research

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Conclusion Statin therapy reduces the risk of major cardiovascular events in patients with chronic kidney disease including those receiving dialysis.
Source: European Heart Journal - June 21, 2013 Category: Cardiology Authors: Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M. J., Cass, A., Zhang, H., Wang, H. Tags: Prevention and epidemiology Source Type: research

Cardiovascular Risk Factors and Events in Pancreas-Kidney Transplants
Abstract: Cardiovascular and cerebrovascular disease (CCVD) are major causes of morbidity and mortality among patients with diabetes. Strict control of treatable risk factors that contribute to atherosclerosis is important to reduce the risk of stroke, myocardial infarction, and peripheral arterial disease. Simultaneous pancreas-kidney transplantation (SPKT) may significantly improve these risk factors in patients with type 1 diabetes. We studied 103 SPKT from our center with both organs functioning for metabolic and hypertensive control; body mass index (BMI); immunosuppression; and CCVD events. The 53 females/50 males s...
Source: Transplantation Proceedings - April 1, 2013 Category: Transplant Surgery Authors: L. Martins, I. Fonseca, L. Dias, J. Malheiro, A. Rocha, P. Azevedo, H. Silva, R. Almeida, A.C. Henriques, J. Davide, A. Cabrita Tags: Renal Transplantation Source Type: research

Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
Conclusions: Although statins reduce absolute CVD risk in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with progressive CKD, partly offset these gains. Low-cost generic statins appear cost-effective for primary prevention of CVD in patients with mild-to-moderate CKD and hypertension.
Source: Journal of the American College of Cardiology - March 20, 2013 Category: Cardiology Authors: Kevin F. Erickson, Sohan Japa, Douglas K. Owens, Glenn M. Chertow, Alan M. Garber, Jeremy D. Goldhaber-Fiebert Tags: Cardiovascular Risk Source Type: research

Characteristics of serum C1q-binding adiponectin in patients on maintenance hemodialysis: C1q-binding adiponectin in hemodialysis patients
Conclusions: Low serum C1q-APN and C1q-APN/C1q ratio, but not C1q-APN/Total-APN ratio, correlated with ACVD in HD patients.Trial registration: ClinicalTrials.gov: UMIN 000004318https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000005173&language=E
Source: BioMed Central - February 26, 2013 Category: Journals (General) Authors: Ken KishidaNaohiro KishidaMasaaki ArimaHideaki NakatsujiHironori KobayashiTohru FunahashiIichiro Shimomura Source Type: research